Autoimmunity, Rheumatology and Connective Tissue Disease in O&G
Autoimmune rheumatology is not a list of rare diseases. It is the biology of lost tolerance, misdirected inflammation, autoantibody injury, immune-complex deposition, complement activation, vasculopathy, fibrosis and thrombosis. Those mechanisms sit inside everyday O&G questions: recurrent pregnancy loss, pre-eclampsia mimics, fetal growth restriction, fetal heart block, thrombocytopenia, renal disease, VTE risk, contraception safety, drug safety, wound healing and maternal critical illness.
The Primary level should make a candidate dangerous to superficial explanations. "Pregnancy is immunosuppressed" is too crude. "SLE causes miscarriage" is too vague. "APS is blood too thick" is incomplete. The useful approach is to ask:
| Question | Why it matters in O&G |
|---|---|
| Which immune compartment is abnormal? | B cell, T cell, complement, neutrophil, macrophage, endothelium or fibroblast |
| Is the injury antibody, immune complex, cell-mediated, thrombotic or fibrotic? | Determines fetal risk, maternal organ risk and drug logic |
| Does IgG cross the placenta? | Explains anti-Ro/La fetal heart block, neonatal lupus and alloimmune disease |
| Is complement being consumed or activated? | Distinguishes SLE flare patterns from hypertensive placental disease |
| Is the placenta a target, a bystander or both? | Explains APS, FGR, pre-eclampsia and fetal loss |
| Does treatment protect the mother, the placenta, the fetus or all three? | Explains hydroxychloroquine, aspirin, heparin and pregnancy-compatible immunosuppression |
The Central Concept: Tolerance Failure
The immune system must recognise pathogens without destroying self. Tolerance is the set of mechanisms that delete, silence or regulate self-reactive lymphocytes. Autoimmune disease appears when tolerance fails and tissue injury becomes self-sustaining.
Central Tolerance
Central tolerance occurs in primary lymphoid organs.
| Site | Cell type | Main tolerance mechanism | Consequence of failure |
|---|---|---|---|
| Thymus | T cells | Negative selection deletes high-affinity self-reactive T cells; regulatory T cells are generated | Autoreactive T helper and cytotoxic cells escape |
| Bone marrow | B cells | Receptor editing, deletion or anergy of self-reactive B cells | Autoreactive B cells enter circulation |
Central tolerance is powerful but incomplete. Some self-antigens are tissue-specific and are simply not present in the thymus or marrow to select against, and some self-reactive cells escape by chance. The peripheral immune system must therefore police the rest.
The deeper organising idea behind peripheral tolerance is two-signal activation. A lymphocyte that recognises antigen through its receptor (signal one) does not switch on unless it simultaneously receives a co-stimulatory second signal from an activated antigen-presenting cell. That second signal is licensed by danger — tissue damage, dead-cell debris and pathogen-derived molecules mature dendritic cells and switch on their co-stimulatory machinery. Antigen seen without danger (the everyday situation for self) reaches the lymphocyte as signal one alone, which drives anergy or deletion rather than activation. This is why we do not mount an autoimmune attack on skin every time we cut ourselves: the antigen is present, but the response is gated by whether the context says "respond". Autoimmunity is, in part, a failure of this gate — self-antigen presented in an inflammatory, danger-rich context that should never have licensed a response.
Peripheral Tolerance
Peripheral tolerance acts in tissues and lymph nodes after lymphocytes leave the thymus or marrow.
| Mechanism | Basic idea | O&G relevance |
|---|---|---|
| Anergy | Lymphocyte sees antigen without co-stimulation and becomes unresponsive | Prevents harmless antigen responses |
| Deletion | Repeated or inappropriate activation triggers apoptosis | Removes dangerous clones |
| Regulatory T cells | Tregs suppress effector responses through cytokines and cell contact | Important in maternal-fetal tolerance |
| Immune checkpoints | CTLA-4, PD-1 and related pathways restrain activation | Explains why checkpoint-inhibitor cancer drugs can cause autoimmune toxicity |
| Immune privilege and local regulation | Tissue environments limit destructive inflammation | Decidua is a regulated immune site, not an immune-free site |
| Complement regulation | Host cells express proteins that prevent complement attack | Failure or overload contributes to immune-complex disease and thrombotic microangiopathy |
Pregnancy adds a special tolerance problem. The fetus is semi-allogeneic, but the maternal immune system is not simply turned off. Trophoblast, decidua, uterine NK cells, Tregs, complement regulators and unusual HLA expression create a controlled interface. That mechanism is developed in the fetus as an allograft.
Why Autoimmune Disease Loves Reproductive Medicine
Many systemic autoimmune diseases cluster in women of reproductive age. That is not an accident.
| Factor | Mechanism | Clinical consequence |
|---|---|---|
| Sex hormones | Oestrogen, progesterone and prolactin shape B-cell survival, T-cell balance and cytokine tone | Disease activity may change across cycle, pregnancy and puerperium |
| X chromosome biology | Many immune genes are X-linked; X-inactivation escape can increase immune-gene dosage | Female predominance in SLE and related disease |
| Pregnancy immune remodelling | Tolerance, complement, NK-cell and vascular biology are actively altered | Flares, remission or placental disease depending disease |
| Fetal microchimerism | Fetal cells can persist in maternal tissues for years | May participate in repair or immune activation; not a simple cause |
| Infection and molecular mimicry | Pathogen antigens can resemble self-antigens or provide inflammatory co-stimulation | Post-infectious autoimmunity, reactive arthritis concepts |
| Cell death and defective clearance | Nuclear material remains available to immune cells | Central to SLE biology |
| Smoking, UV and environmental triggers | Modify proteins, damage cells and activate innate immunity | RA, SLE flares, skin disease and vascular risk |
| Microbiome | Mucosal immune education and antigen exposure | Emerging relevance in inflammatory disease, not yet routine clinical testing |
The puerperium is especially important. After delivery, there is abrupt placental hormone withdrawal, tissue injury, infection risk, sleep deprivation and immune rebound. Several autoimmune diseases flare postpartum, so "delivered" does not mean "immunologically finished".
The One Mechanism That Predicts Direction of Travel
There is a single immunological idea that explains why pregnancy improves some autoimmune diseases and worsens others, and it is worth fixing firmly in mind. T helper responses can be biased toward a Th1 pattern (cell-mediated, pro-inflammatory, interferon-gamma dominant) or a Th2 pattern (humoral, antibody-supporting, less inflammatory). Successful pregnancy is broadly compatible with a relative shift away from inflammatory Th1 toward Th2, accompanied by an expansion of regulatory T cells. A strong Th1 response at the placental interface is associated with miscarriage and is one reason infection and stress threaten early pregnancy.
That single shift makes a clean prediction:
| Disease character | Dominant driver | Typical pregnancy behaviour | Why |
|---|---|---|---|
| Th1/cell-mediated disease | Inflammatory T cells | Often improves during pregnancy, flares postpartum | The Th1→Th2 shift dampens the driving mechanism, then rebounds after delivery |
| Autoantibody-driven disease | Pathogenic antibody | Can flare during or just after pregnancy | A Th2-supported humoral milieu does not silence (and may support) antibody production |
Rheumatoid arthritis and multiple sclerosis are classically Th1-flavoured and frequently quieten in pregnancy before rebounding postpartum. Systemic lupus erythematosus and myasthenia gravis are antibody-driven and can flare in pregnancy or the puerperium. This is not a rule to apply blindly to an individual patient, but it is the mechanism that makes the clinical pattern comprehensible rather than arbitrary, and it explains why the postpartum window is a high-vigilance period for almost every rheumatic disease.
Classifying Autoimmune Injury by Mechanism
Primary candidates should classify autoimmune disease by tissue mechanism, not by memorising every disease name.
| Mechanism | Core lesion | Examples | O&G bridge |
|---|---|---|---|
| Autoantibody receptor stimulation | Antibody stimulates a receptor | Graves disease, TSH receptor antibody | Fetal/neonatal thyrotoxicosis if antibody crosses placenta |
| Autoantibody receptor blockade | Antibody blocks receptor or function | Myasthenia gravis | Weakness, respiratory risk, neonatal myasthenia |
| Cytotoxic antibody injury | Antibody binds cells and causes destruction through Fc receptors/complement | Immune thrombocytopenia, autoimmune haemolytic anaemia | Maternal thrombocytopenia, anaemia, neonatal cytopenia |
| Immune-complex disease | Antigen-antibody complexes deposit in vessels, kidney, skin or placenta | SLE nephritis, serum-sickness pattern, some vasculitides | Proteinuria, nephritis, pre-eclampsia mimic |
| Antiphospholipid antibody disease | Antibodies to phospholipid-binding proteins activate endothelium, platelets, complement and trophoblast injury | APS | Pregnancy loss, FGR, pre-eclampsia, VTE, thrombocytopenia |
| T-cell/macrophage inflammation | Cellular immune attack and cytokine-driven tissue injury | RA synovitis, inflammatory bowel and some vasculitis patterns | Drug safety, disease activity, prematurity |
| Fibroblast/vascular fibrosis | Immune activation leads to vascular injury and collagen deposition | Systemic sclerosis | Pulmonary hypertension, renal crisis, difficult pregnancy risk |
| Autoinflammation | Innate immune activation without classic autoantibody dominance | Familial Mediterranean fever, inflammasome disorders | Fever syndromes, pregnancy-compatible anti-inflammatory strategy |